Divided Federal Circuit: No Commercial Marketing Of Biologic Without FDA License
WASHINGTON, D.C. — A divided panel of the Federal Circuit U.S. Court of Appeals on July 21 affirmed dismissal of California state unfair competition law (UCL) and conversion claims, but vacated...To view the full article, register now.
Already a subscriber? Click here to view full article